ArticleFrontiers in medicine2025
A meta-analysis of controlled clinical trials comparing peginterferon-α plus nucleos(t)ide analogs versus peginterferon-α monotherapy for HBsAg clearance or seroconversion in patients with chronic hepatitis B.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic hepatitis B virus (HBV) infection remains a major global health challenge. Peginterferon-α (PEG-IFN-α) and nucleos(t)ide analogs (NAs) are standard therapies used to suppress HBV replication. Although HBsAg clearance and seroconversion are ideal therapeutic endpoints, whether PEG-IFN-α combined with NAs offers superior efficacy compared with PEG-IFN-α monotherapy remains controversial. Methods: Controlled clinical trials published between 2000 and 2025 that compared PEG-IFN-α plus NA combination therapy with PEG-IFN-α monotherapy in patients with chronic hepatitis B, with treatment duration ≥ 48 weeks, were included. The primary outcomes were HBsAg clearance and seroconversion. Results: Eleven trials involving 2,439 patients were identified and analyzed. After 48 weeks of treatment, the HBsAg clearance rate was significantly higher in the combination therapy group than in the monotherapy group [odds ratio (OR) = 1.59, 95% confidence interval (CI): 1.01-2.52, Conclusion: PEG-IFN-α promotes HBsAg clearance and seroconversion. Combination therapy with PEG-IFN-α plus NAs yields higher short-term clearance than monotherapy; however, sustained benefits appear to require prolonged treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.